US Stock MarketDetailed Quotes
ACRS Aclaris Therapeutics
- 1.165
- -0.005-0.43%
Trading Apr 25 14:06 ET
82.63MMarket Cap-917P/E (TTM)
1.200High1.140Low837.43KVolume1.190Open1.170Pre Close970.99KTurnover1.66%Turnover RatioLossP/E (Static)70.93MShares11.12052wk High0.53P/B58.70MFloat Cap0.59052wk Low--Dividend TTM50.39MShs Float33.880Historical High--Div YieldTTM5.13%Amplitude0.590Historical Low1.159Avg Price1Lot Size
Aclaris Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -15.92%-78.33M | 64.63%-6.76M | -214.15%-24.56M | -5.02%-20.65M | -25.68%-26.35M | -29.60%-67.57M | -11.95%-19.12M | 26.30%-7.82M | -60.92%-19.67M | -71.43%-20.97M |
| Net income from continuing operations | -1.81%-88.48M | 94.60%-1.49M | -46.66%-29.26M | -44.01%-29.57M | -49.87%-28.16M | 4.35%-86.91M | -21.18%-27.64M | 5.65%-19.95M | -13.06%-20.53M | 34.66%-18.79M |
| Depreciation and amortization | 8.28%863K | 20.00%228K | 13.47%219K | 5.83%218K | -4.81%198K | -13.65%797K | -3.55%190K | 1.05%193K | -16.60%206K | -27.78%208K |
| Deferred tax | ---367K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non cash items | -672.34%-26.9M | -470.42%-26.3M | -22.73%1.7M | 55.88%-1.5M | 33.33%-800K | -80.69%4.7M | 222.73%7.1M | 144.44%2.2M | -170.83%-3.4M | -107.30%-1.2M |
| Change In working capital | 885.69%9.39M | 470.47%13.27M | -156.95%-3.16M | 898.64%3.68M | -24.42%-4.4M | 11.02%-1.2M | -590.37%-3.58M | 11.19%5.55M | 112.52%368K | -22.71%-3.53M |
| -Change in receivables | 33.81%186K | -57.52%48K | 112.50%85K | 6,475.00%255K | -1,920.00%-202K | -6.71%139K | -39.89%113K | -68.75%40K | 96.72%-4K | 77.78%-10K |
| -Change in prepaid assets | 42.68%-1.32M | 239.92%7.98M | -466.27%-7.69M | -165.21%-731K | -564.89%-874K | 59.16%-2.29M | -1.66%-5.7M | -59.75%2.1M | 137.71%1.12M | 108.36%188K |
| -Change in payables and accrued expense | 995.63%10.52M | 161.62%5.25M | 30.01%4.44M | 654.21%4.15M | 10.53%-3.32M | -76.73%960K | -59.08%2.01M | 1,081.32%3.42M | -580.13%-749K | -534.53%-3.71M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -15.92%-78.33M | 64.63%-6.76M | -214.15%-24.56M | -5.02%-20.65M | -25.68%-26.35M | -29.60%-67.57M | -11.95%-19.12M | 26.30%-7.82M | -60.92%-19.67M | -71.43%-20.97M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 266.01%46.22M | 179.42%7.55M | 2,573.29%32.53M | 7.36%-19.66M | -13.81%25.8M | 107.53%12.63M | 129.45%2.7M | 103.23%1.22M | 53.33%-21.22M | 139.74%29.93M |
| Net PPE purchase and sale | -116.36%-1.31M | -320.00%-441K | 44.00%-84K | -24.19%-231K | -237.20%-553K | -96.43%-605K | 47.50%-105K | -167.86%-150K | -257.69%-186K | ---164K |
| Net investment purchase and sale | 259.17%47.53M | 184.68%7.99M | 2,286.10%32.62M | 7.63%-19.43M | -12.44%26.35M | 107.91%13.23M | 131.27%2.81M | 103.63%1.37M | 53.68%-21.04M | 139.96%30.1M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 266.01%46.22M | 179.42%7.55M | 2,573.29%32.53M | 7.36%-19.66M | -13.81%25.8M | 107.53%12.63M | 129.45%2.7M | 103.23%1.22M | 53.33%-21.22M | 139.74%29.93M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -63.35%26.71M | 32.43%49K | -690.91%-87K | -63.27%26.74M | 0 | -67.62%72.87M | 1,950.00%37K | 99.90%-11K | -46.41%72.81M | -99.97%30K |
| Net issuance payments of debt | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net common stock issuance | -63.28%26.71M | --0 | --0 | ---- | ---- | -69.46%72.74M | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -40.13%94K | 32.43%49K | --15K | -63.86%30K | --0 | -89.24%157K | --37K | --0 | -92.04%83K | -91.11%37K |
| Net other financing activities | -200.00%-102K | --0 | ---- | ---- | ---- | 98.91%-34K | --0 | 86.90%-11K | 33.33%-16K | 99.77%-7K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -63.35%26.71M | 32.43%49K | -690.91%-87K | -63.27%26.74M | --0 | -67.62%72.87M | 1,950.00%37K | 99.90%-11K | -46.41%72.81M | -99.97%30K |
| Net cash flow | ||||||||||
| Beginning cash position | 65.55%45.28M | -36.68%39.04M | -54.37%31.15M | 23.06%44.72M | 65.55%45.28M | 23.96%27.35M | 15.02%61.65M | -39.83%68.26M | 3.05%36.34M | 23.96%27.35M |
| Current changes in cash | -130.11%-5.4M | 105.12%838K | 219.35%7.89M | -142.52%-13.57M | -106.17%-555K | 239.16%17.93M | 37.62%-16.38M | 88.95%-6.61M | -59.17%31.92M | -31.89%8.99M |
| End cash Position | -11.92%39.88M | -11.92%39.88M | -36.68%39.04M | -54.37%31.15M | 23.06%44.72M | 65.55%45.28M | 65.55%45.28M | 15.02%61.65M | -39.83%68.26M | 3.05%36.34M |
| Free cash flow | -16.81%-79.63M | 62.53%-7.2M | -209.29%-24.64M | -5.20%-20.89M | -27.32%-26.91M | -30.00%-68.17M | -11.26%-19.22M | 25.28%-7.97M | -61.75%-19.85M | -72.77%-21.13M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg